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INTRODUCTION
India was the first country in the world to launch a Family Planning Programme, as early as 1952, with the main aim of controlling its population. Hence over the years India's National Family Planning Programme too has evolved with a shift in focus from merely population control to more critical issues of saving the lives and improving the health of mothers and children through use of reversible spacing methods leading to reduction in unwanted, closely spaced and mistimed pregnancies and thus avoiding pregnancies with higher risks and chances of unsafe abortions. Concerted efforts by the government have resulted in the decline of unmet need for family planning from 25.4% (DLHS-I) to 21.3% (DLHS-III) but approximately 4.2 crore couples still have an unmet need for contraception (1.6 crore for spacing and 2.6 crore for limiting). 1, 2 percent among women aged 15-24 years. 3 A woman's reproductive right -including the right to decide the number, timing and spacing of her children -is absolutely fundamental to women empowerment and equality. 4 The choice of contraceptives available to the women are many and also the efficacy of individual contraceptive device differs. The advanced contraceptive devices available nowadays have minimal side effects and utmost efficacy. The use of safe and effective contraception is the need of the hour in India. Individual preferences and socio-economic conditions of the people play a major role in acceptance of a contraceptive method. In the Indian scenario, much of the women have no role in making of reproductive decisions. The percentage of unwanted births increases with the mother's age, ranging from 1 percent of births to women less than 20 years of age to 33 percent of births to women aged 45-49 years. 3 In this context, contraceptive counselling should be an integrated part of any abortion care and postpartum care to help women avoid another unplanned or unwanted pregnancy. Amongst popular methods offered like barrier contraception, Pills, IUCD and sterilization, injection Depot medroxy progesterone (DMPA) has been found to provide effective, long acting and reversible contraception in lactating mother and post-abortal patients. Added advantage is that it is to be given by intramuscular route and hence not much training is needed for the person administering the injection. [5] [6] [7] [8] [9] The major problem with contraceptive pills and few other methods is the need for regular use. So, use of long acting contraception makes people free from daily usage of contraceptive pills or any other method. Even with long acting contraception, the acceptance of intra-uterine devices and injectable forms differs. Poor compliance from the contraceptive users also compels the health care professionals to advice for long acting contraceptive methods like Inj, DMPA, which has been part of the contraceptive programs of many countries for more than 20 years. 10, 11 And also, women are highly motivated and receptive to accept family planning (FP) methods during the postpartum period. 12 Hence this study was undertaken to study the acceptance of inj DMPA among women seeking contraception from a tertiary health care institute.
Objectives
• To describe the profile of women utilizing Inj.
DMPA as a contraceptive at government tertiary care institute in Mandya. • To determine the compliance of Inj. DMPA utilization among these women. • To assess the factors affecting discontinuation of DMPA utilization.
METHODS
A record based study was conducted over a period of 18 months (Jan 2018 to Jun 2019) among the women who utilized Inj DMPA contraception at tertiary care government hospital, Mandya.
Those who has chosen inj. Depot Medroxy Progesterone Acetate (DMPA) in the age group of 18 to 40 years as contraceptive recorded in the registers were included in this study. Women had received injection DMPA 150 mg IM intramuscularly during the first week of menses, immediate post abortal or at 6 weeks of post-partum period. The ethics committee approval was taken prior to start of the study.
A total of 266 women were included in the study and their follow-up visits were noted subsequently from the records. The subjects received DMPA injections every 3 months in the study period. The available information like age, parity, timing of administration, information provider regarding DMPA injection that were entered during initiation of inj. DMPA and details regarding discontinuation of inj. DMPA that was collected and recorded in the register were entered into the proforma. The collected data was entered in Microsoft excel and analysed.
Inclusion criteria
• Women in the age group of 18 to 40 years who had taken inj. DMPA for contraception.
Exclusion criteria
• Hypertension, diabetes, liver disorder, vaginal bleeding of unknown etiology.
RESULTS
The mean age of the participants was 25.18±4.248 years, the minimum age being 19 years and the maximum being 40 years. and nullipara (0.8%), as shown in Table 2 . Most of the women (56%), who had taken Inj. DMPA were in the lactational period, the remaining in the interval period (25.2%) and post abortal period (18.4%) as depicted in Table 3 . Most of the women were made aware about this method of contraception by health care providers, which constituted doctors (54.8%), ASHA/ANM workers (32.3%) as depicted in Table 4 . Table 5 indicates the number of patients taking the subsequent DMPA injections in the follow up period. The total number had reduced to 118 for the 2 nd injection, 98 for the 3rd injection and 90 for the 4 th injection. Nearly half of the subjects (54.8%) reported irregular bleeding as the most common side effect, followed by amenorrhoea (36.09%), scanty periods (5.63%), weight gain (3.0 %) and the rest with mood changes (1.87%) as depicted in Table 6 . The Table 7 shows the reason for discontinuation of inj. DMPA. The most common reason being irregular spotting per vagina contributing to 53.9% of discontinuation, followed by amenorrhoea 14.7%, wanted to change contraceptive method 19.3% and planning pregnancy 11.93%.
DISCUSSION
In our study, the mean age of the participants was 25.18±4.248 years, the minimum age being 19 years and the maximum being 40 years.
Majority of them were in the age group of 21 to 25 years (48.5%) followed by 26-30 years (28.2%), ≤20 years (13.2%), 31-35 years (7.9%) and ≥36 years (2.3%). Similar findings where in the highest uptake was among women ≥25 years of age (78%) was seen in a multicentric study done by Benson J et al. 13 The majority 2/3 rd (64.3%) of uptake of inj DMPA in our study were primipara, only 0.8% nullipara and the rest being multipara. In a study done by Patel A et al in Ahmedabad, 84% patients were multi para and 10% were primipara. 8 This difference may be because of the different study setting and the socio-cultural factors. Most of the women (56%), who had taken Inj. DMPA were in the lactational period, the remaining in interval period (25.2%) and post abortal period (18.4%). These findings of DMPA uptake in post-delivery are similar to the study done by Patel A et al (post-delivery-55%), Rai L et al, (51%) and Nautival R et al (42%). 6, 8, 14 In our study, the total number of subjects who had taken Inj. DMPA had reduced to 118 for the 2 nd injection and to 98 for the 3 rd injection and 90 for the 4th injection. Four doses of injection DMPA during the study period was received by only 33.8% women Nearly half of the subjects (54.8%) reported irregular bleeding as the most common side effect, followed by amenorrhoea (36.09%), scanty periods (5.2%), weight gain (3.0 %) and the rest with mood changes (1.87%). These findings are similar to the findings in study done by Patel A et al and Rai L et al. 6, 8 The most common reason for discontinuation of inj DMPA in our study being irregular spotting per vagina contributing to 53.97% of discontinuation, followed by amenorrhoea (14.7%), wanted to change contraceptive method (19.3%) and planning pregnancy (11.9%). 6, 15 
